Clear cell papillary renal cell carcinoma: A distinct histopathologic and molecular genetic entity

American Journal of Surgical Pathology

Volumn 32, Issue 8, 2008, Pages 1239-1245

  Gobbo, Stefano ^a,b   Eble, John N ^a   Grignon, David J ^a   Martignoni, Guido ^b   MacLennan, Gregory T ^c   Shah, Rajal B ^d   Zhang, Shaobo ^a   Brunelli, Matteo ^b   Cheng, Liang ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Classification; Clear cell papillary renal cell carcinoma; Cytogenetics; End stage renal disease; Fluorescence in situ hybridization; Immunohistochemistry; Kidney; Neoplasia

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CARBONATE DEHYDRATASE IX; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 7; PARAFFIN; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CELL STRUCTURE; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME ANALYSIS; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY FAILURE; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL; Y CHROMOSOME; CHRONIC KIDNEY FAILURE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; MIDDLE AGED; NOMENCLATURE; PATHOLOGY;

CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KIDNEY FAILURE, CHRONIC; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; TERMINOLOGY AS TOPIC;

EID: 49249115537     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318164bcbb     Document Type: Article

References (33)

1. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31:1149-1160.
2. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
3. Brunelli M, Eble JN, Zhang S, et al. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol. 2003;16:1053-1059.
4. Brunelli M, Eble JN, Zhang S, et al. Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma. Mod Pathol. 2003;16:1060-1063.
5. Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18:161-169.
6. Cossu-Rocca P, Eble JN, Delahunt B, et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol. 2006;19:488-493.
7. Cossu-Rocca P, Zhang S, Roth LM, et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Mod Pathol. 2006;19:611-615.
8. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinico-pathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537-544.
9. Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int. 2002;61:2201-2209.
10. Eble J, Sauter G, Epstein J, et al. Tumours of the kidney. In: IARC, ed. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press;2004.
11. Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendroglio-mas. J Neuropathol Exp Neurol. 2004;63:314-322.
12. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
13. Fuzesi L, Gunawan B, Bergmann F, et al. Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3p. Histopathology. 1999;35:157-161.
14. Greene FL, Page DL, Flemming ID, et al. AJCC cancer staging manual. New York: Springer-Verlag;2002.
15. Hughson MD, Bigler S, Dickman K, et al. Renal cell carcinoma of end-stage renal disease: an analysis of chromosome 3, 7, and 17 abnormalities by microsatellite amplification. Mod Pathol. 1999;12: 301-309.
16. Ikeda R, Tanaka T, Moriyama MT, et al. Proliferative activity of renal cell carcinoma associated with acquired cystic disease of the kidney: comparison with typical renal cell carcinoma. Hum Pathol. 2002;33:230-235.
17. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology. 1993;22:135-139.
18. Jones TD, Eble JN, Wang M, et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res. 2005;11: 7226-7233.
19. Kernek KM, Brunelli M, Ulbright TM, et al. Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. Mod Pathol. 2004;17:1309-1313.
20. Khurana KK, Truong LD, Verani RR. Image analysis of proliferating cell nuclear antigen expression and immunohistochem-ical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma. Mod Pathol. 1998;11:339-346.
21. Kim MK, Kim S. Immunohistochemical profile of common epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol. 2002;10:332-338.
22. Konda R, Sato H, Hatafuku F, et al. Expression of hepato-cyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol. 2004;171: 2166-2170.
23. Martignoni G, Brunelli M, Gobbo S, et al. Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol. 2007;29:41-49.
24. Peces R, Martinez-Ara J, Miguel JL, et al. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. Nephrol Dial Transplant. 2004;19:2789-2796.
25. Rioux-Leclercq NC, Epstein JI. Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. Arch Pathol Lab Med. 2003;127:E89-E92.
26. Salama ME, Worsham MJ, DePeralta-Venturina M. Malignant papillary renal tumors with extensive clear cell change: a molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch Pathol Lab Med. 2003;127:1176-1181.
27. Steiner G, Sidransky D. Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am J Pathol. 1996;149:1791-1795.
28. Sule N, Yakupoglu U, Shen SS, et al. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005;29:443-451.
29. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141-153.
30. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76.
31. Truong LD, Choi YJ, Shen SS, et al. Renal cystic neoplasms and renal neoplasms associated with cystic renal diseases: pathogenetic and molecular links. Adv Anat Pathol. 2003;10: 135-159.
32. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741-746.
33. Yamaguchi S, Yoshihiro S, Matsuyama H, et al. The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. Clin Genet. 2003;63: 184-191.